1. |
Parathyroid hormones for postmenopausal osteoporosis |
|
Inpharma Weekly,
Volume &NA;,
Issue 1349,
2002,
Page 2-2
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
2. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1349,
2002,
Page 3-3
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
3. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1349,
2002,
Page 4-4
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
4. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1349,
2002,
Page 5-5
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
5. |
Emtricitabine shows antiviral activity in hepatitis B |
|
Inpharma Weekly,
Volume &NA;,
Issue 1349,
2002,
Page 6-6
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
6. |
Gefitinib shows promise in NSCLC |
|
Inpharma Weekly,
Volume &NA;,
Issue 1349,
2002,
Page 7-9
Allan Drew,
Raewyn Poole,
Preview
|
|
摘要:
The epidermal growth factor receptor (EGFR) inhibitor gefitinib [ZD 1839, 'Iressa'] is effective in the treatment of non-small-cell lung cancer (NSCLC), according to results from the IDEAL*1 and IDEAL 2 studies presented at the 38th Annual Meeting of the American Society of Clinical Oncology (ASCO) [Orlando, US; May 2002]. These studies showed that gefitinib doses of 250 and 500 mg/day had comparable efficacy with respect to objective response rates and improvements in disease-related symptoms and quality of life (QOL), but that the lower dose was better tolerated.
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
7. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1349,
2002,
Page 9-9
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
8. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1349,
2002,
Page 10-10
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
9. |
IRIS study: imatinib mesylate superior in first-line treatment of CML |
|
Inpharma Weekly,
Volume &NA;,
Issue 1349,
2002,
Page 11-12
Raewyn Poole,
Preview
|
|
摘要:
Imatinib mesylate [STI 571; 'Gleevec', 'Glivec'], a selective inhibitor of the bcr-abl protein tyrosine kinase, is more effective and better tolerated than the current standard treatment of interferon-α plus cytarabine as first-line therapy for chronic myeloid leukaemia (CML), according to results from the IRIS*study presented at the 38th Annual Meeting of the American Society of Clinical Oncology (ASCO) [Orlando, US; May 2002]. Significantly greater rates of cytogenetic and haematological response, and progression-free survival, were reported in recipients of imatinib mesylate, compared with interferon-α plus cytarabine.'Imatinib should now be considered as the standard first-line therapy for chronic myeloid leukaemia',said Dr Brian Druker from Oregon Health Sciences University, US, who presented the results.
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
10. |
Smoking cessation therapies ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1349,
2002,
Page 12-12
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|